ye7 casino slot

EXCLUSIVE Donald Trump announces he is making Kimberly Guilfoyle his ambassador to Greece in stunning move Guilfoyle is a former Fox News host and a big Trump fundraiser By ROB CRILLY, CHIEF U.S. POLITICAL CORRESPONDENT FOR DAILYMAIL.COM IN WASHINGTON, D.C. Published: 17:35 EST, 10 December 2024 | Updated: 18:24 EST, 10 December 2024 e-mail 32 shares 136 View comments Donald Trump announced Tuesday he was appointing ex-Fox News host Kimberly Guilfoyle as his ambassador to Greece . Guilfoyle, 55, studied international law and entered public life as a prosecutor in San Francisco and Los Angeles , but entered the Trump orbit as fiancee to the president-elect's son Don Jr , 46. 'Her extensive experience and leadership in law, media, and politics along with her sharp intellect make her supremely qualified to represent the United States, and safeguard its interests abroad,' Trump said in a Truth Social post. 'Kimberly is perfectly suited to foster strong bilateral relations with Greece, advancing our interests on issues ranging from defense cooperation to trade and economic innovation.' The announcement comes just hours after Daily Mail published photographs of Don Jr. hand-in-hand with the Palm Beach socialite , Bettina Anderson, showing his days with Guilfoyle are clearly over. Don Jnr and Guilfoyle began dating in 2018 and became engaged in 2020. However, Daily Mail has reported extensively that their relationship is all but over since September. Donald Jr. continued to be photographed with 55-year-old Guilfoyle after our revelation, but she has not been snapped with him since November 12 – and was reported to have been 'blindsided'. 'There are a ton of people vying for this. It is one of the hottest posts in the world,' said a source familiar with the president-elect's thinking. 'Not just because it's an amazing place place to live, but because it's a hotbed of activity with everything that is happening in Syria , throughout the middle east, and the migrant crisis.' The source added that Guilfoyle, aside from her relationship with Don Jr. had known Trump for 20 years, and raised hundreds of millions of dollars for his campaigns. 'He wants her to represent him on the world stage,' the source added. Kimberly Guilfoyle is the favorite to be Donald Trump's next ambassador to Greece Guilfoyle was a host on Fox News for more than a decade and has known Trump for 20 years 'She studied international law and will be amazing spokeswoman for Donald Trump. 'She'll be the Jackie O of the MAGA movement.' Guilfoyle was assistant district attorney in San Francisco from 2000 to 2004. But it was her marriage to Democratic politician Gavin Newsom that brought into the public eye, when she was first lady of San Francisco during his first two years as mayor of that city. Insiders said that experience would help her cope with the demands of being Trump's representative overseas. Guilfoyle was an energetic campaigner for Trump and appeared on stage with the family at the election night party in West Palm Beach. She addressed foreign policy during her convention speech in Milwaukee. 'In our vision, America will combat foreign aggressors and ensure our service members are protected, not abandoned, as they carry out their dangerous missions abroad, because we know we can only have peace through strength,' she said in July. Donald Trump, Jr., and Bettina Anderson hold hands leaving Buccan restaurant in Palm Beach, Florida on Monday Donald Trump, Jr., and Bettina Anderson leave Buccan together on Monday night She appeared with other members of the Trump family in their box at the Republican National Convention in Milwaukee, Wisconsin, in July Guilfoyle addressed the party faithful on day three of the Republican National Convention But the appointment comes as her fiancee Don Jr. has been repeatedly pictured with Bettina Anderson , 38, around Palm Beach, suggesting his six-year engagement in well an truly over. The new couple's latest date saw them attend exclusive hotspot Buccan for two hours to celebrate Anderson's birthday. The restaurant is just three miles from Bettina's townhouse, where Don often stays. They looked every bit a new couple, with Don Jr holding her Bettina's hand as they left the venue just before 10pm. Guilfoyle's new role means she will likely be swapping life in Florida for Jefferson House, the American ambassador's residence in the Greek capital Athens. It comes with a swimming pool in the backyard and enough reception space to entertain hundreds of dignitaries. It was named for Thomas Jefferson who held up Greek democracy as the most important influence on the founding of the American republic. Donald Trump Jr Politics Greece Los Angeles Share or comment on this article: Donald Trump announces he is making Kimberly Guilfoyle his ambassador to Greece in stunning move e-mail 32 shares Add commentGPL now has 67MW of backup power; projects underway to improve infrastructureye7 casino slot 。

Eli Lilly & Co. stock underperforms Wednesday when compared to competitors

The Swans stunned Pride Park into silence with less than two minutes on the clock when Zan Vipotnik sent a bullet past Jacob Widell Zetterstrom before Ronald slotted home his first of the season in the 14th minute. Cyrus Christie brought Tom Barkhuizen down inside the box and Nathaniel Mendez-Laing dispatched the resulting penalty to cut the deficit in half and, despite piling on the pressure, Derby succumbed to a second home defeat of the season. Williams told a press conference: “We started the game very well, we were good up until we scored the second goal then we lost the grip on the game and I thought Derby were the better team. “The next thing for us we have to be able to maintain that level throughout the game and we weren’t able to do that to be quite honest today. “They made it difficult, reacted very well after the second goal and didn’t go under, far from it.” Swansea leapfrogged their opponents into the top half of the table with their sixth win of the season and took three points back to south Wales following two last-minute defeats by Burnley and Leeds heading into the match. Williams added: “We’ve recently conceded late goals but they’re a very resilient group and we saw it out in the end. “We’ve dominated games a lot but probably failed to score when we’ve been that dominant and tonight we managed to score the goals when we were dominant. “We scored the goals at the right time today.” Derby had been unbeaten in their last three matches coming into this one but Paul Warne put defeat down to a poor start. He said: “We conceded two and didn’t get close enough, weren’t aggressive enough, not enough body contact and looked soft, that’s my fault. “Maybe I didn’t message it properly. Sometimes it doesn’t come down to shape and tactics but I thought that was what the difference was. “Credit Swansea for the win but after the 25 mins it looked like we would score. I really enjoyed it, that’s the truth. I had 70 minutes of a team giving everything, I don’t think we’ve had that many attempts in the Championship this season. “It’s a rude awakening, last year we would’ve won that 4-2.”

PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. VINC , a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq. Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work. As part of this workforce reduction, Dr. Ahmed Hamdy, Chairman and Chief Executive Officer (CEO), has stepped down as CEO but will remain as Chairman. Dr. Raquel Izumi has stepped down as President and Chief Operations Officer and taken over as Acting CEO in a consulting capacity. Alexander Seelenberger has stepped down as Chief Financial Officer, and Kevin Hass, the Company's Vice President and Controller, has taken over as Acting Chief Financial Officer. Mr. Seelenberger has agreed to provide ongoing assistance in a consulting capacity to assist the Company as it pursues its strategic efforts. "This strategic transaction highlights Vincerx's commitment to develop ADCs with improved safety profiles that allow patients to thrive on—rather than endure—their cancer therapies," said Raquel Izumi, Ph.D., Acting Chief Executive Officer. "Oqory's anti-TROP2 ADC has shown favorable efficacy and safety in the clinic. Among approximately 150 treated patients, results include an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer (TNBC; n=30). Unlike other TROP2 ADCs in Phase 3, no cases of interstitial lung disease or Grade 3 and above stomatitis have been reported. Oqory's Phase 3 studies of OQY-3258 are ongoing to confirm these promising findings." About OQY-3258 (also known as ESG401) OQY-3258 is Oqory's anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. OQY-3258 has shown efficacy in these patients, including reduction of brain metastasis and responses in heavily pretreated patients. To date, OQY-3258 has exhibited a differentiated safety profile vs. Trodelvy and other TROP2 ADCs in Phase 3 development. Notably, no interstitial lung disease or ocular surface events have been observed. Gastrointestinal effects have been mild and mainly Grade 1/2. Neutropenia and leukopenia have been the major AEs, which were manageable and did not result in discontinuation of study drug. OQY-3258 is being evaluated in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer ( NCT06732323 ) and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer ( NCT06383767 ). About Oqory, Inc. Oqory, Inc. is an innovator in the field of ADCs with expertise in advancing targeted cancer therapies. The Company's pipeline includes multiple ADC programs, with two currently in clinical development and several next-generation ADCs in preclinical stages. These programs are designed to address critical unmet needs in indications such as breast cancer, non-small cell lung cancer, small cell lung cancer, multiple myeloma, and other metastatic solid tumors. Powered by a proprietary ADC platform, Oqory is delivering therapies that have demonstrated promising efficacy and safety paving the way for improved patient outcomes. About Vincerx Pharma, Inc. Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx's pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which has completed a Phase 1 monotherapy study; a preclinical ADC, VIP924; and VersAptxTM, a versatile, next-generation bioconjugation platform. Vincerx is based in Palo Alto, California, and has a research subsidiary in Monheim, Germany. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "suggest," "seek," "intend," "plan," "goal," "potential," "on-target," "on track," "project," "estimate," "anticipate," or other comparable terms. All statements other than statements of historical facts included in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, the entry into a definitive merger agreement; the anticipated terms and closing of the merger, the $20 million equity investment, and the amount and timing of the interim financing; the expected ownership structure and value to Vincerx stockholders upon closing of the merger; the anticipated benefits of a merger transaction; and the clinical results of Oqory's product candidates. Forward-looking statements are neither historical facts nor assurances of future performance or events. Instead, they are based only on current beliefs, expectations, and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside Vincerx's control. Actual results, conditions, and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions, and events to differ materially from those indicated in the forward-looking statements include, but are not limited to, Vincerx's capital requirements, availability and sufficiency of capital, and cash runway; the ability of the parties to enter into a definitive merger agreement and the final terms thereof; the parties' ability to satisfy the conditions precedent to the merger, including stockholder approval; the closing of the merger; the risk that any definitive agreement is terminated after it is entered into but before consummation of any proposed merger;; Vincerx's reliance on receipt of interim funding; market acceptance of the combined company; risks associated with clinical development of the Vincerx and Oqory product candidates; general economic, financial, legal, political, and business conditions; and the risks and uncertainties set forth in Vincerx's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and subsequent reports filed with the Securities and Exchange Commission by Vincerx. Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements. Vincerx and the Vincerx logo are trademarks of Vincerx. This press release also contains trademarks and trade names that are the property of their respective owners. Contacts: Gabriela Jairala Vincerx Pharma, Inc. gabriela.jairala@vincerx.com Totyana Simien Inizio Evoke Comms totyana.simien@inizioevoke.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Stephen A. Smith 'closes in on huge new ESPN contract' after rejecting opening $18m-a-year offer

Evangelos ‘Angelo’ Papadopoulos, Flint coney island icon, dies at 89